БАЛАЛАРДАҒЫ ФИБРОБЛАСТТАРДЫҢ ӨСУ ФАКТОРЫ 23 (FGF-23) ЖӘНЕ СОЗЫЛМАЛЫ БҮЙРЕК АУРУЫ
##semicolon##
https://doi.org/10.31082/1728-452X-2020-221-222-11-12-43-48##semicolon##
фибробласттардың өсу факторы 23##common.commaListSeparator## фосфатонин##common.commaListSeparator## балалар нефрологиясы##common.commaListSeparator## созылмалы бүйрек ауруы##common.commaListSeparator## минералды және сүйек бұзылыстары##article.abstract##
Chronic kidney disease (CKD) in children is a complex medical and social problem in healthcare. One of the serious complications is mineral bone disorder (MBD), the pathogenesis of which is related to a new biomarker of bone origin fibroblast growth factor 23 (FGF-23).
The aim. To study the features of fibroblast growth factor 23 (FGF-23) in children with chronic kidney disease.
Material and methods. A cross-sectional study was carried out on 73 children with CKD and 14 healthy children. Inclusion criteria: chronic kidney disease stage 1-5, written informed consent of the participants. The exclusion criteria: tubulopathy, infectious and inflammatory processes, oncological diseases, kidney transplant, condition after surgery, taking glucocorticosteroids, calcium and vitamin D drugs., We took fasting blood samples of participants and carried out an enzyme-linked immunosorbent assay in order determine the level of FGF-23 (Biomedica Medizinprodukte GmbH, Austria). The obtained data were analyzed using IBM SPSS, version 22 (New York, USA).
Results and discussion. In healthy children, the median (Q1-Q3) level of FGF-23 in serum was
0.65 (0.22-0.98) pmol/l, in patients with stage 1 CKD it was 0.65 (0.22-1.08) pmol/l. At stage 2, the level of FGF-23 significantly increased in comparison with healthy individuals and with patients of stage 1, p≤0.05. Further, there is a gradual increase by stages, p≤0.05. Thus, in stage 3 patients, the median FGF-23 value was 1.9 (1.15-3.5) pmol/l, at stage 4 3.55 (2.48-6.35) pmol/l, at 5 stages 14 (7.518.75) pmol/l. As a percentage, there were 7.1% of patients at the stage 1 with increased levels of phosphatonin, at stage 2 53.3%, at stage 3 69.2%, respectively. At stages 4 and 5, absolutely 100% of patients had high levels of FGF-23. At the same time, FGF-23 did not depend on gender, age, birth weight and type of renal replacement therapy at stage 5, p>0.05.
Conclusions. Thus, in our study, we determined the features of changes FGF-23 in serum in children at various stages of CKD. The obtained results allow us to consider FGF-23 as a predictor of the clinical course of CKD.
##submission.citations##
Brück K, Stel V, Fraser S, et al. Translational research in nephrology: Chronic kidney disease prevention and public health. Clin Kidney J. 2015;8(6):647–655. PMID: 26613019. DOI: 10.1093/ckj/sfv082
Bikbov B, Purcell C, Levey A, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733. PMID: 32061315. DOI: 10.1016/S0140- 6736(20)30045-3
Stanifer J, Muiru A, Jafar T, et al. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31:868–874. PMID: 27217391. DOI: 10.1093/ndt/gfv466
Harambat J, van Stralen K, Kim J, et al. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27:363–373. PMID: 21713524, DOI: 10.1007/s00467-011-1939-1
Becherucci F, Roperto R, Materassi M, et al. Chronic kidney disease in children. Clin. Kidney J. 2016;9(4):583–591. DOI: 10.1093/ ckj/sfw047
Kanatbayeva AB, Kabulbayev KA, Naushabayeva AYe, et al. Results of the screening for chronic kidney disease in population of Almaty-city. Nephrologiya i dializ = Nephrology and dialysis. 2012;14(2):109-113. (In Russ.)
Gansevoort R, Correa-Rotter R, Hemmelgarn B, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-352. DOI: 10.1016/ S0140-6736(13)60595-4
Salević P, Radović P, Milić N, et al. Growth in children with chronic kidney disease: 13 years follow up study. J Nephrol. 2014;27(5):537–544. PMID: 24756972. DOI: 10.1007/s40620-014- 0094-8
Molchanova MS, Petrosyan EK, Kazymova SE, et al. Analysis of growth and weight disorders in children with stage II-V chronic kidney disease in Russia according to the Russian Registrar of Children with CKD. Klinicheskaya nephrologiya = Clinical nephrology. 2011;22(8):26-30. (In Russ.)
Riminucci M, Collins M, Fedarko N, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Journal of Clinical Investigation. 2003;112(5):683–692. DOI: 10.1172/ JCI18399
Siomou E, Stefanidis C. FGF-23 in children with CKD: A new player in the development of CKD-mineral and bone disorder. Nephrol. Dial. Transplant. 2012;27(12):4259–4262. PMID: 22848110. DOI: 10.1093/ndt/gfs315
Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009;297(2):282–291. PMID: 19515808, doi: 10.1152/ ajprenal.90742.2008.
Gutierrez O., Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–592. PMID: 18687639. DOI: 10.1056/ NEJMoa0706130
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737–747. PMID: 22622492. DOI: 10.1038/ki.2012.176
Jean G, Terrat J, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009;24(9): 2792–2796. PMID: 19395730. DOI: 10.1093/ndt/gfp191
Gutiérrez O. Fibroblast Growth Factor 23 and the Last Mile. CJASN 2020;15(9):1355–1357. DOI: 10.2215/CJN.13631119
Sinha M, Turner C, Dalton R, et al. Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5. Nephrol. Dial. Transplant. 2012;27(12):4361–4368. PMID: 22529162. DOI: 10.1093/ ndt/gfs109
Magnusson P, Hansson S, Swolin-Eide D. A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. Scand J Clin Lab Invest. 2010;70(1):15–20. PMID: 19929273. DOI: 10.3109/00365510903359245
Liu D, Alvarez-Elías A, Wile B, et al. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: A cross-sectional study. BMC Nephrol.2017;18(1):204. DOI: 10.1186/s12882-017-0623-5
The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) serves to update the 2002 KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification following a decade of focused research and clinical practice in CKD. Kidney International Supplements. 2013;3:136–150. DOI:10.1038/kisup.2012.72
